SCHEMBL30765829

SCHEMBL30765829

CC(C)[C@@H](Nc1cnc(-c2ccccc2F)n(CC(=O)NCc2cc3cnccc3[nH]2)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.34

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
F3 P13726 4/20 0.34
F2 P00734 4/20 0.33
ELANE P08246 1/20 0.32
LMNA P02545 1/20 0.32
MAPK1 P28482 2/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31
ALDH1A1 P00352 2/20 0.31
HPGD P15428 1/20 0.31
CMA1 P23946 1/20 0.31
NTRK1 P04629 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558576 0.91 F3 (0.35) F3F2LMNAMAPK1PRSS1
SCHEMBL30765439 0.91 F3 (0.35) F3F2LMNAMAPK1PRSS1
SCHEMBL30765945 0.91 F3 (0.34) F3F2LMNAMAPK1NPC1
SCHEMBL30765595 0.90 F3 (0.35) F3F2LMNAMAPK1NPC1
SCHEMBL30765565 0.88 F3 (0.36) F3F2ELANEMAPK1PRSS1
SCHEMBL30765885 0.87 MAPK1 (0.34) F3F2MAPK1PRSS1PRSS2
SCHEMBL30765751 0.85 F3 (0.34) F3F2LMNAMAPK1NPC1
SCHEMBL30765617 0.85 F3 (0.34) F3F2LMNAMAPK1NPC1
SCHEMBL30765543 0.84 ELANE (0.39) F3F2ELANEMAPK1CMA1
SCHEMBL31558547 0.83 PDE2A (0.41) F3F2ELANEMAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed